news
Novartis Lp(a) Drug Fails Heart Trial Despite Crushing Biomarker
Novartis reported at the American Heart Association meeting that pelacarsen slashed lipoprotein(a) levels but failed to reduce heart attacks or strokes in a trial of 8,324 patients. The surprise outcome shakes longevity medicine, where elevated Lp(a) has long been treated as a critical genetic target. Lowering the particle count did not protect the vessel.
Novartis reported at the American Heart Association meeting that pelacarsen slashed lipoprotein(a) levels but failed to reduce heart attacks or strokes in a trial of 8,324 patients. The surprise outcome shakes longevity medicine, where elevated Lp(a) has long been treated as a critical genetic target. Lowering the particle count did not protect the vessel.
The architecture take
Every longevity clinic selling out-of-pocket panels just hit an awkward reality check. For five years, I watched doctors obsess over lipoprotein(a) as the ultimate hidden vascular boogeyman, promising that gene-silencing shots would fix the risk once they cleared Phase 3. I admit I expected this trial to validate the entire premise. Instead, Novartis gave pelacarsen to over 8,000 patients with established heart disease, wiped out their circulating Lp(a) numbers, and saw zero reduction in actual heart attacks or strokes.
I used to worry about my own borderline numbers after an early biomarker panel. But this readout proves that moving a surrogate lab marker doesn't mean you spared the blood vessel. When knocking a particle down by 80% fails to stop clinical events, baseline endothelial stress and chronic inflammation clearly drive the damage. Keep training your VO2max, keeping blood sugar flat, and managing blood pressure. The magic bullet for genetic lipids isn't arriving on schedule.